Opthea Limited American Depositary Receipt (UKJ2)

Overview

Opthea Limited is an Australian-based, clinical-stage biopharmaceutical company that specializes in innovating and developing therapeutic solutions primarily for eye diseases. The company's research and development efforts are anchored in a robust intellectual property portfolio that extensively covers Vascular Endothelial Growth Factors (VEGF) such as VEGF-C, VEGF-D, and VEGF Receptor-3. These are crucial in the treatment of diseases triggered by blood and lymphatic vessel growth, alongside vascular leakage. Initially known as Circadian Technologies Limited, Opthea rebranded in December 2015 to better reflect its refined focus and direction in the biopharmaceutical domain. Opthea Limited was initially established in 1984, showcasing a long-standing presence and experience in the biotech industry, and is headquartered in South Yarra, Australia.

Products and Services

• Sozinibercept (OPT 302)

As the flagship product candidate of Opthea Limited, Sozinibercept (OPT 302) embodies a new frontier in the treatment of eye diseases, specifically targeting wet age-related macular degeneration (AMD) and diabetic macular edema (DME). This novel therapy takes the form of a soluble vascular endothelial growth factor receptor-3 (VEGFR-3), purposefully designed to inhibit the pathways that contribute to abnormal blood and lymphatic vessel growth and leakage. Currently under Phase 3 clinical development, Sozinibercept represents Opthea's commitment to delivering innovative solutions in the realm of ophthalmology, promising a new therapeutic avenue for patients grappling with these challenging conditions.